Alpine Associates Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Alpine Associates Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,140,000	Closed	-$20M	–	64
2021 Q3	$20M	Buy	+1,140,000	New	+$13.3M	0.65%	37

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Alpine Associates Management's TRIL Position: Q4 2021 in Review

Alpine Associates Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 1,140,000 shares — an estimated $20M sold.

Alpine Associates Management first reported a position in TRIL in Q3 2021 and held it in 1 quarter. The position peaked at $20M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Alpine Associates Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Alpine Associates Management sold 1,140,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $20M.
Alpine Associates Management first reported a position in Trillium Therapeutics Inc. in Q3 2021 and held it in 1 quarter.
Alpine Associates Management's Trillium Therapeutics Inc. position peaked at $20M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Alpine Associates Management's 13F filing for Q4 2021, filed 8 Feb 2022.